Obesity poses a significant health challenge in the United States. More than 40% of the population has a body mass index (BMI) exceeding 30, according to the CDC. It’s particularly startling that around 20% of American children fall into the obese category, which comes as a surprise to many.
This condition is linked to serious health complications, including diabetes, strokes, heart disease, and liver issues. Clearly, tackling this problem requires a multifaceted approach. Changes in diet and exercise are essential, but access to healthy food options and education about healthy living are critical, especially for individuals across all socioeconomic groups.
The initiative known as Maha, or “Make America Healthy Again,” aims to target these obesity rates, particularly among children. If successful, it could have a significant positive impact on weight and health-related outcomes.
However, addressing obesity in adults can be more challenging. Many find it difficult to shed pounds, despite making lifestyle adjustments. Changes in metabolism with age and the development of metabolic dysfunction, often referred to as metabolic syndrome, can complicate weight loss efforts.
Recent findings suggest that many individuals struggling with obesity may need medical assistance in addition to lifestyle changes. The rise in popularity of GLP-1 agonists, such as Wegovy and Zepbound, over the past two years underscores the growing recognition of the need for medical interventions in treating obesity.
Currently, approximately 15 million people in the U.S.—or about 6% of the population—are engaged in GLP-1 weight loss treatments, a number expected to grow. While many individuals experience a weight loss of 10% to 25% with these medications, most do not continue the treatment long-term; around 80% stop within a year.
Factors like gastrointestinal side effects, the need for injections, and high costs often deter patients from maintaining GLP-1 treatments. Unfortunately, many regain the weight once they cease taking the medication.
There is acknowledgment among healthcare practitioners and the pharmaceutical industry that obesity requires a nuanced treatment approach. Effective long-term weight management post-GLP-1 is increasingly seen as an unmet need. For patients who cannot use GLP-1, alternative options should be available.
Combating obesity effectively necessitates a combination of lifestyle changes and prescription medications. To truly address this pressing health crisis, collaboration between the pharmaceutical industry and organizations like MAHA is essential. Both prevention and treatment play crucial roles in safeguarding national health.
